At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Tivozanibdrug
Likely dose
Tivozanib 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
In Brief
A Phase 2 clinical trial evaluating Tivozanib for Recurrent Epithelial Ovarian Cancer and 2 related conditions. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJun 2013
Primary CompletionOct 2018
Study CompletionMay 2021
TodayJul 2026
First PostedMay 15, 2013
Enrollment StartJun 6, 2013
Primary CompletionOct 2, 2018
Study CompletionMay 11, 2021
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.1 years ago
Interventions
Tivozanibdrug
1.5 mg Given PO (orally)days 1-21 or every 28 day cycle